Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jacques Leclaire is active.

Publication


Featured researches published by Jacques Leclaire.


The Journal of Steroid Biochemistry and Molecular Biology | 2006

Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women

Fernand Labrie; Alain Bélanger; Patrick Bélanger; René Bérubé; Céline Martel; Leonello Cusan; José Luis Gomez; Bernard Candas; Isabelle Castiel; Véronique Chaussade; Claire Deloche; Jacques Leclaire

Despite the long series of cohort studies performed during the last 20 years, the correlation between serum testosterone and any clinical situation believed to be under androgen control in women has remained elusive. This is likely related to the recent finding that the androgens made locally in large amounts in peripheral tissues from the precursor dehydroepiandrosterone (DHEA) act in the same cells where synthesis takes place and are not released in significant amounts in the circulation, thus making unreliable the measurement of serum testosterone as marker of total androgenic activity. The objective is to determine if serum androgen glucuronides can be replaced by testosterone or another steroid as measure of androgenic activity. Since the glucuronide derivatives of androgens are the obligatory route of elimination of all androgens, these metabolites were measured by liquid chromatography tandem mass spectrometry under basal conditions in 377 healthy postmenopausal women aged 55-65 years as well as in 47 premenopausal women aged 30-35 years while testosterone was assayed by gas chromatography mass spectrometry. No correlation was found between the serum concentration of testosterone and that of androsterone glucuronide (ADT-G) or androstenediol glucuronide (3alpha-diol-G), the androgen metabolites which account for the total pool of androgens. The present data show that measurement of the total pool of androgens reflected by the serum levels of ADT-G and 3alpha-diol-G cannot be replaced by serum testosterone or any other steroid, including DHEA or DHEA sulphate. These findings may have implications for women with androgen deficiency involving osteoporosis, obesity, type 2 diabetes, sexual dysfunction, loss of muscular strength and a series of other clinical situations affecting womens health. Measuring ADT-G and 3alpha-diol-G might identify cases of true androgen deficiency and provide an opportunity to offer appropriate androgen therapy.


The Journal of Steroid Biochemistry and Molecular Biology | 2007

Metabolism of DHEA in postmenopausal women following percutaneous administration

Fernand Labrie; Alain Bélanger; Patrick Bélanger; René Bérubé; Céline Martel; Leonello Cusan; José Luis Gomez; Bernard Candas; Véronique Chaussade; Isabelle Castiel; Claire Deloche; Jacques Leclaire

The marked decline in serum dehydroepiandrosterone (DHEA) with age is believed to play a role in health problems associated with aging, these health issues being potentially preventable or reversible by the exogenous administration of DHEA. In the present study, liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS) and gas chromatrography/mass spectrometry (GC/MS) were used to measure the serum levels of DHEA and 11 of its metabolites in seventy-five 60-65-year-old Caucasian women who received 3g of 0.1%, 0.3%, 1.0% or 2.0% DHEA cream or placebo applied twice daily on the face, upper chest, arms and legs. The serum levels of DHEA increased 574% over control at the 2.0% DHEA dose while the sum of the androgen metabolites androsterone glucuronide (ADT-G), 3alpha-androstenediol-3G (3alpha-diol-3G) and 3alpha-diol-17G increased by only 231%. On the other hand, serum testosterone and dihydrosterone were increased by 192% and 275%, respectively, above basal levels compared to 139% and 158% for estrone and estradiol. Such data show that the transformation of exogenous DHEA in postmenopausal women is preferentially into androgens rather than into estrogens. On the other hand, the present data indicate that serum DHEA measurements following DHEA supplementation in postmenopausal women are an overestimate of the formation of active androgens and estrogens and suggest a decreased efficiency of transformation of DHEA into androgens and estrogens with aging.


Skin Pharmacology and Physiology | 2000

Percutaneous Absorption of Sunscreens in vitro: Interspecies Comparison, Skin Models and Reproducibility Aspects

Florence Benech-Kieffer; P. Wegrich; R. Schwarzenbach; G. Klecak; T. Weber; Jacques Leclaire; Hans Schaefer

Appropriate evaluation of sunscreens is required to provide better knowledge of their safety and efficacy. One of the most important elements of this evaluation is the assessment of percutaneous absorption. In vitro methods are largely used for such assessments, and the accuracy of the measurements generated with these methods depends on the use of a proper methodology. This study was designed to evaluate an in vitro protocol for investigating the percutaneous absorption of two sunscreens under standardized experimental conditions. Octyl methoxycinnamate and benzophenone 4 were each incorporated in a typical oil-in-water emulsion and tested separately. Salicylic acid was tested as a reference compound. In vitro percutaneous absorption was evaluated using two species, the pig and human, and two models, full-thickness and split-thickness skin. The reproducibility of study results was evaluated by comparing the data generated by two industrial laboratories, L’Oréal and Hoffmann-La Roche. The correlation of quantitative data between pig skin and human skin was very good, and the split-thickness skin model seemed to be more appropriate for measuring the absorption of sunscreens. Results obtained for salicylic acid demonstrated the relevance of the protocol in terms of prediction of in vivo percutaneous absorption. Finally, the comparison of pig skin data between the two laboratories demonstrated a good correlation and underlined the need for a standardized in vitro procedure.


The Journal of Steroid Biochemistry and Molecular Biology | 2009

Expression profiles of phases 1 and 2 metabolizing enzymes in human skin and the reconstructed skin models Episkin™ and full thickness model from Episkin™

Van Luu-The; Daniel Duche; Corinne Ferraris; Jean-Roch Meunier; Jacques Leclaire; Fernand Labrie

BACKGROUND Episkin and full thickness model from Episkin (FTM) are human skin models obtained from in vitro growth of keratinocytes into the five typical layers of the epidermis. FTM is a full thickness reconstructed skin model that also contains fibroblasts seeded in a collagen matrix. OBJECTIVES To assess whether enzymes involved in chemical detoxification are expressed in Episkin and FTM and how their levels compare with the human epidermis, dermis and total skin. METHODS Quantification of the mRNA expression levels of phases 1 and 2 metabolizing enzymes in cultured Episkin and FTM and human epidermis, dermis and total skin using Realtime PCR. RESULTS The data show that the expression profiles of 61 phases 1 and 2 metabolizing enzymes in Episkin, FTM and epidermis are generally similar, with some exceptions. Cytochrome P450-dependent enzymes and flavin monooxygenases are expressed at low levels, while phase 2 metabolizing enzymes are expressed at much higher levels, especially, glutathione-S-transferase P1 (GSTP1) catechol-O-methyl transferase (COMT), steroid sulfotransferase (SULT2B1b), and N-acetyl transferase (NAT5). The present study also identifies the presence of many enzymes involved in cholesterol, arachidonic acid, leukotriene, prostaglandin, eicosatrienoic acids, and vitamin D3 metabolisms. CONCLUSION The present data strongly suggest that Episkin and FTM represent reliable and valuable in vitro human skin models for studying the function of phases 1 and 2 metabolizing enzymes in xenobiotic metabolisms. They could be used to replace invasive methods or laboratory animals for skin experiments.


European Journal of Dermatology | 2008

Supplementation with oral probiotic bacteria protects human cutaneous immune homeostasis after UV exposure-double blind, randomized, placebo controlled clinical trial

Josette Péguet-Navarro; Colette Dezutter-Dambuyant; Timo Buetler; Jacques Leclaire; Hans Smola; Stephanie Blum; Philippe Bastien; Lionel Breton; Audrey Gueniche

There is now strong evidence that probiotic bacteria can regulate inflammatory immune responses. Here, we analyzed whether oral supplementation with the probiotic bacterial strain Lactobacillus johnsonii (La1) could interfere with skin immune status following UV exposure. A randomized, double-blind, placebo controlled clinical trial was conducted with 54 healthy volunteers receiving either La1 or placebo, during six weeks prior to solar-simulated UV irradiation. Blister roofs and skin biopsies were recovered 1, 4 and 10 days after UV exposure from un-irradiated and irradiated skin and used for immunohistochemical analysis and mixed epidermal cell lymphocyte reaction (MECLR), respectively. La1 supplementation did not prevent the UV-induced phenotypic maturation of Langerhans cells (LCs) or the decrease in MECLR in irradiated skin samples, one day post-irradiation. On day 4, MECLR was still decreased in the placebo group, with a parallel reduction in the CD1a LC marker in irradiated epidermis. In contrast, the allostimulatory capacity of epidermal cells was totally recovered in the La1 group correlating with the normalization of CD1a expression within the epidermis. For the first time, the results provide evidence that ingested probiotic bacteria accelerate the recovery of skin immune homeostasis after UV-induced immunosuppression.


The Journal of Steroid Biochemistry and Molecular Biology | 2008

Changes in serum DHEA and eleven of its metabolites during 12-month percutaneous administration of DHEA

Fernand Labrie; Leonello Cusan; José-Luis Gomez; Céline Martel; René Bérubé; Patrick Bélanger; Véronique Chaussade; Claire Deloche; Jacques Leclaire

Healthy postmenopausal women aged 60-65 years (n=150) were randomized to receive twice daily application on the skin of 3g of a 0.3% dehydroepiandrosterone (DHEA) or placebo emulsion for 12 months. Serum DHEA and eleven of its metabolites were measured at screening and on day 1, as well as at 1, 3, 6, 9 and 12 months to study long-term metabolism. While serum DHEA and androst-5-ene-3beta, 17beta-diol (5-diol) increased by 203% and 178%, respectively, on average, during the 12-month period, the sum of concentrations of the metabolites of androgens, namely androsterone glucuronide (ADT-G), androstane-3alpha,17beta-diol-3G and -17G increased by only 71% while usually non statistically significant changes of 30%, 17% and 20% were observed for estrone (E(1)), estradiol (E(2)) and E(1) sulfate (E(1)-S), respectively. Despite the return of serum DHEA to normal premenopausal values with the present DHEA treatment regimen, the 65% decrease in the androgen pool found in this group of postmenopausal women is in fact corrected by only 24%, thus remaining 41% below the values found in normal premenopausal women. In fact, the changes in serum DHEA observed after percutaneous DHEA administration are a 186% overestimate of the true changes in androgen formation while the overestimate of estrogen production is even much higher. On the other hand, the pharmacokinetics of the steroids are stable over the 12-month period with no significant induction or decrease of activity of the enzymatic systems transforming DHEA predominantly into androgens.


Toxicology in Vitro | 2010

In vitro assessment of eye irritancy using the Reconstructed Human Corneal Epithelial SkinEthic HCE model: application to 435 substances from consumer products industry.

José Cotovio; Marie-Hélène Grandidier; Damien Lelièvre; Christelle Bremond; Carolle Amsellem; Saber Maloug; Jean-Marc Ovigne; Sophie Loisel-Joubert; Aline Van Der Lee; Anne-Marie Minondo; Christophe Capallere; Béatrice Bertino; Nathalie Alépée; Estelle Tinois-Tessonneaud; Anne De Brugerolle de Fraissinette; Jean-Roch Meunier; Jacques Leclaire

The 7th amendment of the EU Cosmetics Directive led to the ban of eye irritation testing for cosmetic ingredients in animals, effective from March 11th 2009. Over the last 20years, many efforts have been made to find reliable and relevant alternative methods. The SkinEthic HCE model was used to evaluate the in vitro eye irritancy potential of substances from a cosmetic industry portfolio. An optimized protocol based on a specific 1-h treatment and a 16-h post-treatment incubation period was first assessed on a set of 102 substances. The prediction model (PM) based on a 50% viability cut-off, allowed to draw up two classes (Irritants and Non-Irritants), with good associated sensitivity (86.2%) and specificity (83.5%). To check the robustness of the method, the evaluated set was expanded up to 435 substances. Final performances maintained a high level and were characterized by an overall accuracy value > 82% when using EU or GHS classification rules. Results showed that the SkinEthic HCE test method is a promising in vitro tool for the prediction of eye irritancy. Optimization datasets were shared with the COLIPA Eye Irritation Project Team and ECVAM experts, and reviewed as part of an ongoing progression to enter an ECVAM prospective validation study for eye irritation.


The Journal of Steroid Biochemistry and Molecular Biology | 2008

Pangenomic changes induced by DHEA in the skin of postmenopausal women

Ezequiel Calvo; Van Luu-The; Jean Morissette; Céline Martel; Claude Labrie; B. Bernard; F. Bernerd; Claire Deloche; Véronique Chaussade; Jacques Leclaire; Fernand Labrie

The objective of this study was to explore, for the first time, the changes in the pangenomic profile induced in human skin in women treated with dehydroepiandrosterone (DHEA) applied locally. Sixty postmenopausal women participated in this phase II prospective, randomized, double-blind and placebo-controlled study. Women were randomized to the twice daily local application of 0% (placebo), 0.3%, 1% or 2% DHEA cream. Changes in the pangenomic expression profile were studied using Affymetrix Genechips. Significant changes (p<0.05) in sixty-six DHEA-responsive probe sets corresponding to 52 well-characterized genes and 9 unknown gene sequences were identified. A dose-dependent increase in the expression of several members of the collagen family was observed, namely COL1, COL3 and COL5 as well as the concomitant modulation of SPARC, a gene required for the normal deposition and maturation of collagen fibrils in the dermis. Several genes involved in the proliferation and differentiation of keratinocytes were also modulated. In addition, topical DHEA reduced the expression of genes associated with the terminal differentiation and cornification of keratinocytes. Our results strongly suggest the possibility that DHEA could exert an anti-aging effect in the skin through stimulation of collagen biosynthesis, improved structural organization of the dermis while modulating keratinocyte metabolism.


The Journal of Steroid Biochemistry and Molecular Biology | 2007

Steroid metabolism and profile of steroidogenic gene expression in Episkin™: High similarity with human epidermis

Van Luu-The; Corinne Ferraris; Daniel Duche; Patrick Bélanger; Jacques Leclaire; Fernand Labrie

The skin is a well-recognized site of steroid formation and metabolism. Episkin is a cultured human epidermis. In this report, we investigate whether Episkin possesses a steroidogenic machinery able to metabolize adrenal steroid precursors into active steroids. Episkin was incubated with [14C]-dehydroepiandrosterone (DHEA) and 4-androstenedione (4-dione) and their metabolites were analyzed by liquid chromatography/mass spectrometry (LC/MS/MS). The results show that the major product of DHEA metabolism in Episkin is DHEA sulfate (DHEAS) (88% of the metabolites) while the other metabolites are 7alpha-OH-DHEA (8.2%), 4-dione (1.3%), 5-androstenediol (1.3%), dihydrotestosterone (DHT) (1.4%) and androsterone (ADT) (2.3%). When 4-dione is used as substrate, much higher levels of C19-steroids are produced with ADT representing 77% of the metabolites. These data indicate that 5alpha-reductase, 17beta-hydroxysteroid dehydrogenase (17beta-HSD) and 3alpha-hydroxysteroid dehdyrogenase (3alpha-HSD) activities are present at moderate levels in Episkin, while 3beta-HSD activity is low and represents a rate-limiting step in the conversion of DHEA into C19-steroids. Using realtime PCR, we have measured the level of mRNAs encoding the steroidogenic enzymes in Episkin. A good agreement is found between the mRNAs expression in Episkin and the metabolic profile. High expression levels of steroid sulfotransferase SULT2B1B and type 3 3alpha-HSD (AKR1C2) correspond to the high levels of DHEA sulfate (DHEAS) and ADT formed from DHEA and 4-dione, respectively. 3beta-HSD is almost undetectable while the other enzymes such as type 1 5alpha-reductase, types 2, 4, 5, 7, 8, and 10 17beta-HSD and 20alpha-hydroxysteroid dehydrogenase (20alpha-HSD) (AKR1C1) are highly expressed. Except for UGT-glucuronosyl transferase, similar mRNA expression profiles between Episkin and human epidermis are observed.


Experimental Dermatology | 2010

Large scale study of epidermal recovery after stratum corneum removal: dynamics of genomic response

Peggy Sextius; Claire Marionnet; François-Xavier Bon; Albane Lamy de La Chapelle; Charlotte Tacheau; M. Lahfa; Alain Mauviel; Bruno Bernard; Jacques Leclaire; Françoise Bernerd; Louis Dubertret

Please cite this paper as: Large scale study of epidermal recovery after stratum corneum removal: dynamics of genomic response. Experimental Dermatology 2010; 19: 259–268.

Collaboration


Dive into the Jacques Leclaire's collaboration.

Researchain Logo
Decentralizing Knowledge